Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.77 |
| ▸ | KDR | P35968 | 20/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | LYN | P07948 | 1/20 | 0.77 |
| ▸ | HCK | P08631 | 1/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.77 |
| ▸ | BCR | P11274 | 1/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 0.77 |
| ▸ | AXL | P30530 | 1/20 | 0.77 |
| ▸ | FLT3 | P36888 | 1/20 | 0.77 |
| ▸ | ABL2 | P42684 | 1/20 | 0.77 |
| ▸ | FRK | P42685 | 1/20 | 0.77 |
| ▸ | SYK | P43405 | 1/20 | 0.77 |
| ▸ | MST1R | Q04912 | 1/20 | 0.77 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.77 |
| ▸ | MERTK | Q12866 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570201 | 0.95 | MET (0.74) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL3613344 | 0.95 | MET (0.84) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL13167427 | 0.95 | MET (0.77) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL2670920 | 0.94 | MET (0.72) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL13664129 | 0.94 | MET (0.68) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL2670932 | 0.93 | MET (0.80) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL4557283 | 0.93 | MET (0.72) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL2670912 | 0.93 | MET (0.72) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL3567343 | 0.93 | MET (0.73) | METKDRPLK4MAP4K4ABL1 | |
| SCHEMBL3577604 | 0.93 | MET (0.77) | METKDRAURKAFPR1FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | claimed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | claimed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404846-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885PLK4 1664/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | MET 2/4885KDR 4/4885PLK4 1664/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885PLK4 1664/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MET 3/4885KDR 11/4885PLK4 864/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | MET 2/4885KDR 4/4885PLK4 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.